All Stories

  1. Mefloquine exposure as a cause of sleep disorders among US military personnel and veterans
  2. Trichomonas vaginalis infection and prostate‐specific antigen concentration: Insights into prostate involvement and prostate disease risk
  3. Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma
  4. Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis
  5. RE: “A DECADE OF WAR: PROSPECTIVE TRAJECTORIES OF POSTTRAUMATIC STRESS DISORDER SYMPTOMS AMONG DEPLOYED US MILITARY PERSONNEL AND THE INFLUENCE OF COMBAT EXPOSURE”
  6. Mefloquine Exposure May Confound Associations and Limit Inference in Military Studies of Posttraumatic Stress Disorder
  7. Association of Poultry Processing Industry Exposures With Reports of Occupational Finger Amputations
  8. Misclassification and Bias in Military Studies of Mefloquine
  9. A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions
  10. Confounding by Symptomatic Mefloquine Exposure in Military Studies of Post-Traumatic Stress Disorder
  11. Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection
  12. Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data
  13. To Squander the Fighting Strength? Personal Experiences with Preventive Psychiatry and the Dilemma of Wartime Public Mental Health
  14. Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report
  15. Stellate Ganglion Block in the Treatment of Post-traumatic Stress Disorder: A Review of Historical and Recent Literature
  16. The timeliness of the US military response to the 2014 Ebola disaster: a critical review
  17. Considerations in the Repositioning of Mefloquine for Anesthetic Indications
  18. In Reply
  19. Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives
  20. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada
  21. Prohibiting direct medical care by US military personnel in foreign disaster relief: arguments from the Ebola disaster
  22. Bias in military studies of mefloquine
  23. U.S. Military Surveillance of Mental Disorders, 1998–2013
  24. Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection
  25. Unexpected pharmacological and toxicological effects of tafenoquine
  26. Issues in the Prevention of Malaria Among Women at War
  27. Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy
  28. Organic Depersonalization as a Chronic Sequela of Mefloquine Intoxication
  29. The Mefloquine Intoxication Syndrome: A Significant Potential Confounder in the Diagnosis and Management of PTSD and Other Chronic Deployment-Related Neuropsychiatric Disorders
  30. Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy
  31. Population Estimates of Undocumented Incident Traumatic Brain Injuries Among Combat-Deployed US Military Personnel
  32. A Memoir of Mefloquine Amnesia: A Review ofThe Answer to the Riddle Is Meby David Stuart MacLean
  33. Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine
  34. Suicides Among Military Personnel
  35. Outbreak of H3N2 Influenza at a US Military Base in Djibouti during the H1N1 Pandemic of 2009
  36. Re: McGuire JM. The Incidence of and Risk Factors for Emergence Delirium in U.S. Military Combat Veterans. Journal of Perianesthesia Nursing. 2012;27(4):236-45
  37. Falling Rates of Malaria among U.S. Military Service Members in Afghanistan Substantiate Findings of High Compliance with Daily Chemoprophylaxis
  38. Confounding and bias in studies of DMSS vaccination data
  39. Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy
  40. Mass administration of the antimalarial drug mefloquine to Guantánamo detainees: a critical analysis
  41. Mefloquine Gap Junction Blockade and Risk of Pregnancy Loss
  42. Limitations of Postmarketing Surveillance in the Analysis of Risk of Pregnancy Loss Associated With Maternal Mefloquine Exposure
  43. Hallucinations and Persecutory Delusions in Mefloquine-Associated Suicide
  44. Limbic encephalopathy and central vestibulopathy caused by mefloquine: A case report
  45. Prostate-specific antigen concentration in young men: new estimates and review of the literature
  46. Investigating channel blockers for the treatment of multiple sclerosis: Considerations with mefloquine and carbenoxolone
  47. Neuropharmacokinetic Heterogeneity of Mefloquine in the Treatment of Progressive Multifocal Leukoencephalopathy
  48. Mefloquine Blockade of Connexin 36 and Connexin 43 Gap Junctions and Risk of Suicide
  49. Biased Measurement of Neuropsychiatric Adverse Effects of Pediatric Mefloquine Treatment
  50. Serosurvey of Bacterial and Viral Respiratory Pathogens Among Deployed U.S. Service Members
  51. Mefloquine neurotoxicity and gap junction blockade: Critical insights in drug repositioning
  52. MTHFR C677T Genotype As a Risk Factor for Epilepsy Including Post-Traumatic Epilepsy in a Representative Military Cohort
  53. Mefloquine blockade of connexin 43 (Cx43) and risk of pregnancy loss
  54. Malaria in the Republic of Djibouti, 1998-2009
  55. Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration
  56. Mental Health Standards for Combat Deployment
  57. In Response
  58. Active Tuberculosis and Recent Overseas Deployment in the U.S. Military
  59. Hepatitis E Seroprevalence and Seroconversion among US Military Service Members Deployed to Afghanistan
  60. Gastrointestinal Illnesses among French Forces Deployed to Djibouti: French Military Health Surveillance, 2005-2009
  61. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007
  62. Low validity of self-report in identifying recent mental health diagnosis among U.S. service members completing Pre-Deployment Health Assessment (PreDHA) and deployed to Afghanistan, 2007: a retrospective cohort study
  63. Pain and Discomfort in Deployed Helicopter Aviators Wearing Body Armor
  64. Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis
  65. The Effect of Psychiatric Third-Year Rotation Setting on Academic Performance, Student Attitudes, and Specialty Choice
  66. Device-specific rates of needlestick injury at a large military teaching hospital
  67. Cost and Effectiveness of Chlamydia Screening Among Male Military Recruits: Markov Modeling of Complications Averted Through Notification of Prior Female Partners
  68. Suspected Pulmonary Tuberculosis Exposure at a Remote U.S. Army Camp in Northeastern Afghanistan, 2007
  69. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan
  70. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000–2004
  71. Trends in Overweight and Obesity Among 18-Year-Old Applicants to the United States Military, 1993–2006
  72. Rising Hepatitis A Immunity in U.S. Military Recruits
  73. Musical Athletes
  74. Injuries and injury risk factors among members of the United States Army band
  75. Benefits of Serologic Screening for Hepatitis B Immunity in Military Recruits